- 英文名称
- Degarelix
- 分子式
- C82H103ClN18O16
- 分子量
- 1632.26
- 中文别名
- 地加瑞克游离碱; (S)-N-(4-((2S,5S,8R,11R,14R)-2-(((R)-1-(((S)-1-(((S)-1-((S)-2-(((R)-1-氨基-1-氧代丙-2-基)氨基甲酰基)吡咯烷-1-基)-6-(异丙基氨基)-1-氧代己-2-基)氨基)-4-甲基-1-氧代戊-2-基)氨基)-1-氧代-3-(4-脲苯基)丙-2-基)氨基甲酰基)-11-(4-氯苄基)-5-(羟甲基)-14-(萘-2-基甲基)-4,7,10,13,16-五氧代-8-(吡啶-3-基甲基)-3,6,9,12,15-五氮杂十七基)苯基)-2,6-二氧代六氢嘧啶-4-甲酰胺; Ac-D-2-Nal-D-4-Cpa-D-3-Pal-Ser-4-amino-Phe(L-4,5-dihydroorotyl)-4-ureido-D-Phe-Leu-Lys(isopropyl)-Pro-D-Ala-NH2; DEGARELIX游离; 地加瑞克-D7; 化合物 DEGARELIX; (S)-N-(4-((2S,5S,8R,11R,14R)-2-(((R)-1-(((S)-1-(((S)-1-((S)-2-(((R)-1-Amino-1-oxopropan-2-yl)carbamoyl)pyrrolidin-1-yl)-6-(isopropylamino)-1-oxohexan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-1-oxo-3-(4-ureidophenyl)propan-2-yl)carbamoyl)-11-(4-chlorobenzyl)-5-(hydroxymethyl)-14-(naphthalen-2-ylmethyl)-4,7,10,13,16-pentaoxo-8-(pyridin-3-ylmethyl)-3,6,9,12,15-pentaazaheptadecyl)phenyl)-2,6-dioxohexahydropyrimidine-4-carboxamide; acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-Ser-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-Leu-N6-(1-methylethyl)-L-lysyl-Pro-D-Ala-NH2; Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-hydroorotyl)-D-4Aph(carbamoyl)-Leu-ILys-Pro-D-Ala-NH2; N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-4-[2,6-dioxohexahydropyrimidin-4(S)-ylcarboxamido]-L-phenylalanyl-4-ureido-D-phenylalanyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide; D-Alaninamide, N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-; FirMagon; Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2
- 用途
- 醋酸地加瑞克是促性腺激素释放激素（GnRH）受体拮抗剂，通过与脑下垂体的GnRH受体可逆结合，减少促性腺激素及睾酮释放，发挥抗前列腺癌作用，用于雄激素依赖的前列腺癌患者，对晚期前列腺癌骨转移患者也有良好效果。
